S&P 500 Futures
(0.29%) 5 106.50 points
Dow Jones Futures
(0.63%) 38 623 points
Nasdaq Futures
(0.62%) 17 759 points
Oil
(0.32%) $79.20
Gas
(-0.79%) $2.02
Gold
(0.30%) $2 316.50
Silver
(0.56%) $26.98
Platinum
(0.52%) $967.60
USD/EUR
(-0.09%) $0.931
USD/NOK
(-0.15%) $10.98
USD/GBP
(-0.16%) $0.797
USD/RUB
(0.93%) $91.98

Aktualne aktualizacje dla ImmuPharma PLC [IMM.L]

Giełda: LSE Branża: Pharmaceuticals, Biotechnology & Life Sciences
Upcoming Earnings Alert

5 days till quarter result
(bmo 2024-05-08)

Expected move: +/- 13.16%

Ostatnio aktualizowano2 geg. 2024 @ 18:22

0.25% £ 2.04

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:22):

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives...

Stats
Dzisiejszy wolumen 477 122
Średni wolumen 2.73M
Kapitalizacja rynkowa 8.87M
EPS £0 ( 2023-08-31 )
Następna data zysków ( £0 ) 2024-05-08
Last Dividend £300.00 ( 2021-12-14 )
Next Dividend £0 ( N/A )
P/E -2.04
ATR14 £0.0360 (1.74%)

ImmuPharma PLC Korelacja

10 Najbardziej pozytywne korelacje
10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ImmuPharma PLC Finanse

Annual 2022
Przychody: £0
Zysk brutto: £-117 563 (0.00 %)
EPS: £-0.0126
FY 2022
Przychody: £0
Zysk brutto: £-117 563 (0.00 %)
EPS: £-0.0126
FY 2021
Przychody: £118 350
Zysk brutto: £0.00 (0.00 %)
EPS: £-0.0325
FY 2020
Przychody: £126 667
Zysk brutto: £0.00 (0.00 %)
EPS: £-0.0343

Financial Reports:

No articles found.

ImmuPharma PLC Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)
£0
(N/A)

ImmuPharma PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend £300.00 2021-12-14
Last Dividend £300.00 2021-12-14
Next Dividend £0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 1 --
Total Paid Out £300.00 --
Avg. Dividend % Per Year 240.00% --
Score 4.01 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-05-03)
£0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
4.01
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
2021 £300.00 2 400.00%
2022 £0 0.00%
2023 £0 0.00%
2024 £0 0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for LSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
SEQI.L Dividend Knight 2023-07-27 Quarterly 10 3.85%
ICGC.L Dividend Knight 2023-09-14 Annually 15 1.80%
BISI.L Dividend Knight 2024-01-04 Annually 32 2.05%
WTB.L Dividend Knight 2023-05-25 Annually 33 0.87%
NTV.L Dividend Knight 2023-07-20 Semi-Annually 25 4.03%
EMG.L Dividend King 2023-08-10 Semi-Annually 31 3.60%
SPT.L Dividend Knight 2023-08-10 Semi-Annually 32 1.51%
JD.L Dividend Knight 2023-12-07 Annually 28 0.21%
BUT.L Dividend King 2023-08-03 Quarterly 49 1.28%
PNL.L Dividend Knight 2023-08-24 Quarterly 41 0.75%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-32.541.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-1.0381.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-1.7081.500-10.00-10.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.1690.8009.157.32[1 - 3]
quickRatioTTM0.9700.8009.007.20[0.8 - 2.5]
cashRatioTTM0.1361.500-0.357-0.535[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM-2.581.000-2.07-2.07[3 - 30]
operatingCashFlowPerShareTTM-0.005022.00-0.00167-0.00334[0 - 30]
freeCashFlowPerShareTTM-0.005332.00-0.00267-0.00533[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM-0.3261.000-8.76-8.76[0.2 - 0.8]
operatingProfitMarginTTM-31.511.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.03190.800-3.12-2.50[0.5 - 2]
Total Score-4.45

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-1.9871.000-0.3020[1 - 100]
returnOnEquityTTM-1.7082.50-10.00-10.00[0.1 - 1.5]
freeCashFlowPerShareTTM-0.005332.00-0.00178-0.00533[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.005022.00-0.00167-0.00334[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-3.281.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM-15.931.000-10.000[0.1 - 0.5]
Total Score-3.03

ImmuPharma PLC

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej